Atherosclerotic Cardiovascular Disease

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.

Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.

At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.

Patients with PAH saw a 76% reduction in the composite of morbidity and mortality outcomes with sotatercept treatment.

At ACC.25, Robert S. Rosenson, MD, discusses the efficacy and safety of solbinsiran, an ANGPTL3 inhibitor, in a population with mixed dyslipidemia.

Hosts break down the STRIDE and SOUL trial results and reflect on how they might inform treatment strategies in the respective patient populations.

Four-year results from SOUL at ACC.25 were the first to test the cardiovascular benefits of an oral GLP-1 RA in high-risk type 2 diabetes.

Data from STRIDE at ACC.25 demonstrate semaglutide could provide even greater benefits in type 2 diabetes than previously known.

First Procedure Performed at AHN Wexford Hospital, Demonstrating Network’s Ongoing Commitment to Bringing Complex Cardiovascular Care into the Community

Bhatt previews 3 late-breaking clinical trials being presented at this year's American College of Cardiology Annual Scientific Sessions.

In this episode, hosts discuss the impact of recently launched direct, cash pay options for people using semaglutide and tirzepatide.

Food insecurity remained associated with incident CVD after adjustment for socioeconomic factors among participants in the 2000-2020 CARDIA study period.

A study of 3 large US cohorts found a higher intake of butter was linked to greater mortality rates, while plant-based oil intake lowered total mortality.

Fonarow describes a revised classification of glucose levels that breaks down the normal range into lower and higher levels of associated cardiovascular risk.

The February 2025 cardiology review covers pipeline updates in lipid management, key regulatory acceptances and approvals, and shifting ASCVD trial endpoints.

Dual SGLT1/2 inhibition with sotagliflozin significantly reduced both heart attacks and stroke in a prespecified secondary analysis of the SCORED trial.

Large ASCVD randomized controlled trials in prominent journals often use heterogeneous endpoints, which could influence reported results.

The American Heart Association’s 2025 statistical update confirms cardiovascular diseases claim more US lives than all forms of cancer and accidental deaths.

Awarded to Roche, the Tina-quant® Lipoprotein (a) Gen.2 Molarity assay will be the first 510(k) cleared test measuring Lp(a) in nanomoles per liter (nmol/L).

Only 7% of patients presenting to US emergency departments received cardiac biomarker testing, with 2.8% diagnosed with ACS.

Self-reported primary prevention aspirin use decreased among adults with both low and high ASCVD risk after the release of evidence-based guidelines.

Anti-CGRP monoclonal antibodies for migraine prevention were not linked to increased cardiovascular risk, per a Medicare study, addressing earlier safety concerns.

An economic analysis highlights a cardiovascular polypill's potential to lower healthcare costs and address income-based health disparities.

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.